71-82-9

Basic information

• Product Name: LEVALLORPHAN TARTRATE
• Synonyms: 17-allyl-morphinan-3-otartrate(1:1)(salt);4a-iminoethanophenanthren-6-ol,11-allyl-1,3,4,9,10,10a-hexahydro-2h-1tar;levallorphanhydrogentartrate;levallorphantartrate;levallorphinetartrate;l-levallorphantartrate;lorfan;lorfantartrate
• CAS NO: 71-82-9
• Molecular Formula: C₄H₆O₆*C₁₉H₂₅NO
• Molecular Weight: 433.498
• EINECS: 200-767-3
• Mol File: 71-82-9.mol

Chemical Properties

• Melting Point: 176-177°
• Boiling Point: 660.4°C at 760 mmHg
• Flash Point: 353.2°C
• Appearance: white/solid
• Vapor Pressure: 2.42E-18mmHg at 25°C
• Solubility: H2O: soluble
• PKA: pKa 4.5/6.9(H2O,t =25.0) (Uncertain)
• CAS DataBase Reference: LEVALLORPHAN TARTRATE(CAS DataBase Reference)
• NIST Chemistry Reference: LEVALLORPHAN TARTRATE(71-82-9)
• EPA Substance Registry System: LEVALLORPHAN TARTRATE(71-82-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 36
• WGK Germany: 3
• RTECS: QD0480000
• Hazardous Substances Data: 71-82-9(Hazardous Substances Data)

Usage

Uses

Used in Anti-narcotic Applications:
Levallorphan tartrate is used as an anti-narcotic agent for its ability to counteract the effects of opioid overdose, particularly respiratory depression and sedation. It can be administered in cases of suspected opioid poisoning to reverse the life-threatening symptoms and support the patient's recovery.
Used in Pain Management:
Levallorphan tartrate is used as a narcotic-antagonist analgesic for the management of moderate to severe pain. It provides effective pain relief by binding to opioid receptors in the central nervous system, but with a reduced risk of respiratory depression compared to traditional opioids like morphine.
Used in Counteracting Morphine Effects:
Levallorphan tartrate is used as a countermeasure against the respiratory depression and analgesia caused by morphine sulfate. It can be administered to patients who have been treated with morphine to mitigate the side effects and ensure the patient's safety and comfort during recovery.

InChI:InChI=1/C19H25NO.C4H6O6/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19;5-1(3(7)8)2(6)4(9)10/h2,6-7,13,16,18,21H,1,3-5,8-12H2;1-2,5-6H,(H,7,8)(H,9,10)/t16-,18+,19+;/m0./s1

Upstream product

• 51072-35-6 1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydro-isoquinoline 
• 51072-34-5 N-(2-cyclohex-1-enylethyl)-2-(4-methoxyphenyl)-acetamide 
• 3399-73-3 2-(1-cyclohexenyl)ethylamine 
• 104-01-8 4-Methoxyphenylacetic acid 
• 74570-02-8 4-((S)-1,2,3,4,5,6,7,8-octahydro-[1]isoquinolylmethyl)-phenol 
• 87-69-4 L-Tartaric acid 
• 152-02-3 levallorphan 
• 74570-02-8 (+)-1-(p-hydroxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 51072-36-7 (+)-1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline 

Relevant articles and documents

Method for preparing levallorphan tartrate

The invention provides a method for preparing levallorphan tartrate and belongs to the technical field of drug and chemical synthesis. The method takes methoxyphenylacetic acid and 2-(cyclohexenyl)ethylamine as initial raw materials, and comprises nine reaction steps such as acylation condensation, Bischler-Napieralski ring formation reaction, imine reduction, ether bond hydrolysis, resolution, N-alkylation, Grewe cyclization reaction, and salifying. According to the method, the levallorphan tartrate and each intermediate can be obtained at high yield and high purity, and the method can serve as an industrial method for performing large-scale production.